New non-oral drug delivery systems for Parkinson's disease treatment

Bibliography

• CNS Therapeutics Market Forecast Till 2015, Global Business Intelligence. London, United Kingdom; 2009
   Google Scholar
• Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003;348:1356-64
   PubMed Web of Science ®Google Scholar
• Statistics by Country for Parkinson's disease, Wrong diagnosis; 2010. Available from: www.wrongdiagnosis.com/p/parkinsons_disease/books.htm [Last accessed 18 August 2010]
   Google Scholar
• Therapeutic focus - Parkinson's disease in need of fresh impetus, Evaluate Pharma®; 2009. Available from: www.epvantage.com/Universal/View.aspx?type=Story&id. [Last accessed 8 August 2010]
   Google Scholar
• Fahn S. Levodopa in the treatment of Parkinson's disease. J Neural Transm 2006;71(Suppl):1-15
   Google Scholar
• Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 2004;13(62):47-55
   Web of Science ®Google Scholar
• Montastruc JL, Rascol O, Senard JM. Treatment of Parkinson's disease should begin with a dopamine agonist. Mov Disord 1999;14(5):725-30
   PubMed Web of Science ®Google Scholar
• Weiner WJ. The initial treatment of Parkinson's disease should begin with levodopa. Mov Disord 1999;14(5):716-24
   PubMed Web of Science ®Google Scholar
• Wooten GF. Agonists vs levodopa in PD: the thrilla of whitha. Neurology 2003;60(3):360-2
   PubMed Web of Science ®Google Scholar
• Stefano AD, Sozio P, Lannitelli A, Cerasa LS. New drug delivery strategies for improved parkinson disease therapy. Expert Opin Drug Deliv 2009;6(4):389-404
   PubMed Web of Science ®Google Scholar
• Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991;50:743-55
   PubMed Web of Science ®Google Scholar
• Hely MA, Morris J, Reid WGJ, Sydney multicenter study of Parkinson's disease: non-motor problems dominate at 15 years. Mov Disord 2005;20:190-9
   PubMed Web of Science ®Google Scholar
• Adams JD, Odunze IN. Oxygen free radicals and Parkinson's disease. Free Radic Biol Med 1991;10:161-9
   PubMed Web of Science ®Google Scholar
• Jenner P. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Curr Opin Neurol 2003;16:S3-7
   PubMed Web of Science ®Google Scholar
• Yuan H, Sarre S, Ebinger G, Michotte Y. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease. Brain Res 2004;1026:95-107
   PubMed Web of Science ®Google Scholar
• Horstink M, Tolosa E, Bonuccelli U, Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 2006;13:1170-85
   PubMed Web of Science ®Google Scholar
• Pahwa R, Factor SA, Lyons KE, Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-95
   PubMed Web of Science ®Google Scholar
• Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56:S1-88
   PubMed Web of Science ®Google Scholar
• Siegal T, Zylber-Katz E. Strategies for increasing drug delivery to the brain: focus on brain lymphoma. Clin Pharmacokinet 2002;41:171-86
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Recent advances in blood brain-barrier transport. Annu Rev Pharmacol Toxicol 1988;28:25-39
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu ZZ, Chen SZ. Synthesis of a Dopamimetic Thionated Dipeptide Prodrug of L-DOPA. Chin Chem Lett 2005;16(6):713-15
   Web of Science ®Google Scholar
• Bodor N, Buchwald P, Drug targeting via retrometabolic approaches. Pharmacol Ther 1997;76:1-27
   PubMed Web of Science ®Google Scholar
• Bergley DJ. The blood–brain barrier: principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol 1996;48:136-46
   PubMed Web of Science ®Google Scholar
• Pilar C, Bruno G, Helene C, Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 2001;18(8):1157-66
   PubMed Web of Science ®Google Scholar
• Lambert DM. Rationale and applications of lipids as prodrug carriers. Eur J Pharm Sci 2000;11:S15-27
   PubMed Web of Science ®Google Scholar
• Wu J, Yoon SH, Wu WM, Bodor N. Synthesis and biological evaluation of a brain targeted chemical delivery system of [Nva2]-TRH. J Pharm Pharmacol 2002;54:945-50
   PubMed Web of Science ®Google Scholar
• Kreuter J. Nanoparticlate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001;47:65-81
   PubMed Web of Science ®Google Scholar
• Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. Curr Med Chem 2002;2:241-9
   Google Scholar
• Doran SE, Ren XD, Betz AL, Gene expression from recombinant viral vectors in the central nervous system after blood–brain barrier disruption. Neurosurgery 1995;36:965-70
   PubMed Web of Science ®Google Scholar
• Mathias NR, Hussain MA. Non-invasive systemic drug delivery: developability considerations for alternate routes of administration. J Pharm Sci 2010;99:1-20
   PubMed Web of Science ®Google Scholar
• Oertel W, Ross JS, Eggert K, Adler G. Rationale for transdermal drug administration in Alzheimer disease. Neurology 2007;69:4-9
   PubMed Web of Science ®Google Scholar
• Seeberger LC, Hauser RA. Optimizing bioavailability in the treatment of Parkinson's disease. Neuropharmacol 2007;53:791-800
   PubMed Web of Science ®Google Scholar
• Poewe W, Luessi F. Clinical studies with transdermal rotigotine in early Parkinson's disease. Neurology 2005;65:S11-14
   Google Scholar
• Zareba G. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease. Drugs Today (Barc) 2006;42(1):21-8
   PubMed Web of Science ®Google Scholar
• Chen JJ, Swope DM, Dashtipour K, Lyons KE. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease. Pharmacotherapy 2009;29(12):1452-67
   PubMed Web of Science ®Google Scholar
• Neupro® European summary of product characteristics. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/neupro/emea-combined-h626en.pdf [Last accessed 15 March 2010]
   Google Scholar
• Chaudhuri KR. Crystallisation within transdermal rotigotine patch: is there cause for concern? Expert Opin Drug Deliv 2008;5(11):1169-71
   PubMed Web of Science ®Google Scholar
• General information on Lisuride TDS and Lisuride sc. Available from: www.axxonis.com/projects_e.html [Last accessed 22 October 2010]
   Google Scholar
• Woitalla D, Muller T, Benz S, Horowski R. Transdermal lisuride delivery in the treatment of Parkinson disease. J Neural Transm 2004;68:89-95
   Google Scholar
• Peira E, Scolari P, Gasco MR. Transdermal permeation of apomorphine through hairless mouse skin from microemulsions. Int J Pharm 2001;226(1-2):47-51
   PubMed Web of Science ®Google Scholar
• Addressing unmet need in management of parkinson disease. Drug Deliv Technol 2007;60-63. Available from: www.alteatherapeutics.com/.../OnDrugDelivery_Final.pdf [Last accessed 15 October 2010]
   Google Scholar
• Degim IT, Acarturk F, Erdogan D, Lortlar ND. Transdermal administration of bromocriptine. Bio Pharm Bull 2003;26(4):501-5
   PubMed Web of Science ®Google Scholar
• Chen TF, Chiang CM. Transdermal administration of ropinirole and analogs thereof. US5807570; 1998
   Google Scholar
• Yum Su II, Nelson MK, Campbell PS. Formulations for transdermal delivery of pergolide. WO040139; 1996
   Google Scholar
• Forlando P, Scasso A, Stefeno F. Transdermal drug delivery system for liquid active ingredient. US0087678A1; 2010
   Google Scholar
• Kushnir M, Eliahu H. Apparatus for the transdermal treatment of parkinsons disease. US6746688; 2004
   Google Scholar
• Dipierro G, Steven A. Biosynchronous transdermal drug delivery for parkinsons disease. US0220092; 2008
   Google Scholar
• Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Adv Drug Deliv Rev 2004;56(4):619-58
   PubMed Web of Science ®Google Scholar
• Li LG, Bouwastra AJ, Wolff M, Nugroho KA. Iontophoretic delivery of rotigotine for the treatment of parkinsons disease. US007632859B2; 2009
   Google Scholar
• Laar V, Geest TV, Gubbens-Stibbe JM, Iontophoretic delivery of Apomorphine II: an in vivo study in patients with Parkinson's disease. Pharm Res 1997;14(12):1804-10
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Non-invasive drug delivery to the human brain using endogenous blood–brain barrier transport systems. Pharm Sci Technol Today 1999;2:49-59
   PubMedGoogle Scholar
• Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000;11:1-18
   PubMed Web of Science ®Google Scholar
• Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 2004;56:3-17
   PubMed Web of Science ®Google Scholar
• Van Laar T, Jansen ENH, Essink AWG, Neef C. Intranasal apomorphine in parkinsonian on–off fluctuations. Arch Neurol 1992;49:482-4
   PubMed Web of Science ®Google Scholar
• Sam E, Jeanjean AP, Maloteaux JM, Verbeke N. Apomorphine pharmacokinetics after intranasal and subcutaneous application. Eur J Drug Metab Pharmacokinet 1995;20:27-33
   PubMed Web of Science ®Google Scholar
• Corboy DL, Wagner ML, Sage, JI. Apomorphine for motor fluctuation and freezing in Parkinson's disease. Ann Pharmacother 1995;29:282-8
   PubMed Web of Science ®Google Scholar
• Ugwoke MI, Sam E, Mooter GVD, Nasal mucoadhesive delivery systems of the anti-parkinsonian drug, apomorphine: influence of drug-loading on in vitro and in vivo release in rabbits. Int J Pharm 1999;181:125-38
   PubMed Web of Science ®Google Scholar
• Information on apomorphine nasal powder. Britannia products in developments. Available from: www.britannia-pharm.co.uk/partnerships.shtml#Apo-nasal%20PD [Last accessed 10 October 2010]
   Google Scholar
• Brime B, Ballesteros MP, Frutos P. Preparation and in vitro characterization of gelatin microspheres containing levodopa for nasal administration. J Microencapsul 2000;17(6):777-84
   PubMed Web of Science ®Google Scholar
• Kao HD, Traboulsi A, Itoh S, Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs. Pharm Res 2000;17(8):978-84
   PubMed Web of Science ®Google Scholar
• Byron PR, Patton JS. Drug delivery via the respiratory tract. J Aerosol Med 1994;7:49-75
   PubMedGoogle Scholar
• Jackson B, Bennett DJ, Bartus RT, Emerich DF. Pulmonary delivery for levodopa. Application: US8659 2003079992; 2003
   Google Scholar
• Bartus RT, Emerich DF. Pulmonary delivery in treating disorders of the central nervous system. Application: 006514482B1, 2003
   Google Scholar
• Bartus RT, Emerich DR. Pulmonary delivery in treating disorders of the central nervous system. Application: WOUS293112002024158; 2001
   Google Scholar
• Bartus RT, Emerich D, Snodgrass-Belt P, A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease. J Pharmacol Exp Ther 2004;310:828-35
   PubMed Web of Science ®Google Scholar
• Zheng Y, Marsh KC, Bertz RJ, Pulmonary delivery of a dopamine D-1 agonist, ABT-431, in dogs and humans. Int J Pharm 1999;191:131-40
   PubMed Web of Science ®Google Scholar
• De-Vries ME, Bodde HE, Verhoef JC, Junginger HE. Developments in buccal drug delivery. Crit Rev Ther Drug Carrier Syst 1991;8:271-303
   PubMed Web of Science ®Google Scholar
• Montastruc JL, Rascol O Senard JM, Gualano V. Sublingual Apomorphine in Parkinson's disease: a Clinical and Pharmacokinetic Study. Clinic Neuro Pharm 1991;14(5):373-463
   Google Scholar
• Amarin acquires Parkinson's disease drug candidate oral formulation of apomorphine to treat ‘off’ episode. The free library. Available from: www.amarincorp.com [Last accessed 23 October 2010]
   Google Scholar
• Clarke A, Brewer F, Johnson ES, A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 2003; 110 11):1273-8
   PubMed Web of Science ®Google Scholar
• Zelapar website. Available from: www.zelapar.com [Last accessed 20 October 2010]
   Google Scholar
• H. Seager. Drug delivery products and the Zydis Fast-Dissolving Dosage form. J Pharm Pharmacol 1998;50(4):375-82
   PubMed Web of Science ®Google Scholar
• Eisler T, Eng N, Plotkin C, Calne DB. Absorption of levodopa after rectal administration. Neurology 1981;31(2):215-17
   PubMed Web of Science ®Google Scholar
• Cooper SD, Ismail HA, Frank C. Case report: successful use of rectally administered levodopa-carbidopa. Can Fam Phys 2001;47:112-13
   PubMed Web of Science ®Google Scholar
• Laar TV, Jansen ENH, Neef C, Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. Mov Disord 2004;10(4):433-9
   Google Scholar
• Langer R. Polymer implants for drug delivery in the brain. J Contr Rel 1991;16:53-60
   Web of Science ®Google Scholar
• Kroll RA, Pagel MA, Maldoon LL, Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurgery 1996;38:746-54
   PubMed Web of Science ®Google Scholar
• Tamargo RJ. Brem H. Drug delivery to the central nervous system: a review. Neurosurg 1992;2:259-79
   Google Scholar
• Matsukado K, Inamura T, Nakano S, Enhanced tumor uptake of carboplatin and survival in gliomabearing rats by intracarotid infusion of the bradykinin analog, RMP-7. Neurosurgery 1996;39:125-33
   PubMed Web of Science ®Google Scholar
• Krewson CE, Klarman ML, Saltzman WM. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res 1995;680:196-206
   PubMed Web of Science ®Google Scholar
• Menei P, Benoit JP, Boisdron-Celle M, Drug targeting into the central nervous system by stereotactic implantation of biodegradable microspheres. Neurosurgery 1994;34:1058-64
   PubMed Web of Science ®Google Scholar
• Mittal S, Cohen A, Maysinger D. In vitro effects of brain derived neurotrophic factor released from microspheres. Neuro Report 1994;5:2577-82
   PubMed Web of Science ®Google Scholar
• Benoit JP, Faisant N, Venier-Julienne MC, Menei P. Development of microspheres for neurological disorders: from basics to clinical applications. J Contr Rel 2000;65:285-96
   PubMed Web of Science ®Google Scholar
• McRae A, Dahlstrom A. Transmitter-loaded polymeric microspheres induce regrowth of dopaminergic nerve terminals in striata of rats with 6-OHDA induced parkinsonism. Neurochem Int 1994;25:27-33
   PubMed Web of Science ®Google Scholar
• McRae A, Ling EA, Hjorth S, Catecholamine-containing biodegradable microspheres implants as a novel approach in the treatment of CNS neurodegenerative disease. A review of experimental studies in DA-lesioned rats. Mol Neurobiol 1994;9:191-205
   PubMed Web of Science ®Google Scholar
• Arica B, Kas HS, Moghdam A, Carbidopa/levodopa-loaded biodegradable microspheres: in vivo evaluation on experimental Parkinsonism in rats. J Contr Rel 2005;102:689-97
   PubMed Web of Science ®Google Scholar
• Gill SS, Patel NK, Hotton GR, Direct brain infusion of glial cell line-derived nerotrophic factor in Parkinson disease. Nat Med 2003;9:589-95
   PubMed Web of Science ®Google Scholar
• Patel NK, Bunnage M, Plaha P, Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 2005;57:298-302
   PubMed Web of Science ®Google Scholar
• Slevin JT, Gerhardt GA, Smith, CD Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell linederived neurotrophic factor. J Neurosurg 2005;102:216-22
   PubMed Web of Science ®Google Scholar
• Amgen Incorporated: Amgen's phase 2 study of GDNF for advanced Parkinson's disease fails to meet primary endpoint; six months of treatment showed biological effect but no clinical improvement, 2004. Available form: http://amgen.com/news/viewPR.jsp?id=585632 [Last accessed 12 October 2010]
   Google Scholar
• Pollack A. Patients in test won't get drug, Amgen decides. NY Times, 2005 February 12, C1:C2
   Google Scholar
• Garbayo E, Ansorena E, Lanciego JL, Sustained release of bioactive glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres. Eur J Pham Biophar 2008;69(3):844-51
   PubMed Web of Science ®Google Scholar
• Garbayo E, Montero-Menei CN, Ansorena E, Effective GDNF brain delivery using microspheres—A promising strategy for Parkinson's disease. J Contr Rel 2009;135:119-26
   PubMed Web of Science ®Google Scholar
• Jenkins OF, Jackson DM. Bromocriptine enhances the behavioural effects of apomorphine and dopamine after systemic or intracerebral injection in rats. Neuropharmacology 1986;25(11):1243-9
   PubMed Web of Science ®Google Scholar
• Donovan S, Beach C. Parkinsons disease treatment. US006620415B2; 2003
   Google Scholar
• Shaw KM, Lees AJ, Stern GM. The impact of treatment with levodopa on Parkinson's disease. Quart J Med 1980;49:283-93
   PubMedGoogle Scholar
• Hardie RJ, Malcolm SI, Lees AJ, The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations. Br J clin Pharmac 1986;22:429-36
   PubMed Web of Science ®Google Scholar
• Quinn N, Marsden CD, Parkes JD. Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. Lancet 1982;320(8295):412-15
   Google Scholar
• Juncos JL, Mouradian MM, Fabbrini G, LD methyl ester treatment of Parkinson's disease. Neurology 1987;37(7):1242-50
   PubMed Web of Science ®Google Scholar
• Manson AJ, Hanagasi H, Turner K, Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. Brain 2001;124(2):331-40
   PubMed Web of Science ®Google Scholar
• Kurlan R, Rubin AJ, Miller C, Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 1986;20(2):262-5
   PubMed Web of Science ®Google Scholar
• Kurlan R, Nutt JG, Woodward WR, Duodenal and gastric delivery of levodopa in parkinsonism. Ann Neurol 1988;23(6):589-95
   PubMed Web of Science ®Google Scholar
• Nilsson D, Hansson LE, Johansson K, Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease. Acta Neurol Scand 1998;97(3):175-83
   PubMed Web of Science ®Google Scholar
• Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord 2007;13:13-17
   PubMed Web of Science ®Google Scholar
• Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert opin Pharmacother 2007;8(5):657-64
   PubMed Web of Science ®Google Scholar
• Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Rev Neurother 2006;6(10):1403-11
   PubMedGoogle Scholar
• Available from: www.duodopa.com [Last accessed 20 October 2010]
   Google Scholar
• Nyholm D, Nilsson Remahl AI, Dizdar N, Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005:25;64(2):216-23
   Web of Science ®Google Scholar
• Antonini A, Mancini F, Canesi M, Zangaglia R. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegener Dis 2008;5(3-4):244-6
   PubMed Web of Science ®Google Scholar
• Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson'sdisease: long-term follow-up study of 64 patients. Mov Disord 2002;17(6):1235-41
   PubMed Web of Science ®Google Scholar
• Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease. Drugs Aging 2004;21(11):687-709
   PubMed Web of Science ®Google Scholar
• Chen JJ, Obering C. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease. Clin Ther 2005;27(11):1710-24
   PubMed Web of Science ®Google Scholar
• Stocchi F, Ruggieri S, Carta A, Intravenous boluses and continuous infusions of L-DOPA methyl ester in fluctuating patients with Parkinson's disease. Mov Disord 1992;7:249-56
   PubMed Web of Science ®Google Scholar
• Vaamonde J, Luquin MR, Obeso JA. Subcutaneous lisuride infusion in Parkinson's disease: response to chronic administration in 34 patients. Brain 1991;114:601-17
   PubMed Web of Science ®Google Scholar
• Stocchi F, Ruggieri S, Vacca L, Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 2002;125(9):2058-66
   PubMed Web of Science ®Google Scholar
• Stocchi F, Bramante L, Monge A, Apomorphine and lisuride infusion: a comparative chronic study. Adv Neurol 1993;60:653-5
   PubMedGoogle Scholar
• General information on Lisuride TDS and Lisuride sc. Available from: www.axxonis.com/projects_e.html [Last accessed 20 October 2010]
   Google Scholar
• Kaplitt MG. Another player in gene therapy for Parkinson disease. Nat Rev Neurol 2010;6:7-8
   PubMed Web of Science ®Google Scholar
• Jarraya B. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Science Trans Med 2009;1:1-10
   Web of Science ®Google Scholar
• Kaplitt MG, Feigin A, Tang C, Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007;369:2097-105
   PubMed Web of Science ®Google Scholar
• Marks WJ, Ostrem JL, Verhagen L, Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008;7:400-8
   PubMed Web of Science ®Google Scholar
• Christine CW, Starr PA, Larson PS, Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009;73:1662-9
   PubMed Web of Science ®Google Scholar
• Muramatsu S, Fuzimoto K, Ikeguchi K, Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther 2002;13:345-54
   PubMed Web of Science ®Google Scholar
• Ralph GS, Binley K, Wong LF, Azzouz M. Gene therapy for neurodegenerative and ocular diseases using lentiviral vectors. Clin Sci 2006;110:37-46
   PubMed Web of Science ®Google Scholar
• Burton EA, Glorioso JC, Fink DJ. Gene therapy progress and prospects: Parkinson's disease. Gene Ther 2003;10:1721-7
   PubMed Web of Science ®Google Scholar
• During MJ, Freese A, Deutch AY, Biochemical and behavioral recovery in a rodent model of Parkinson's disease following stereotactic implantation of dopamine-containing liposomes. Exp Neurol 1992;115:193-9
   PubMed Web of Science ®Google Scholar
• Pichandy M, Manisha-Mishra M, Kanaiyan S, Formulation and psychopharmacological evaluation of surfactant modified liposome for parkinsonism disease. Asian J Pharm Clinic Res 2010;3(1):46-54
   Google Scholar
• Ochoteco E, Murillo N, Rodriguez J, In: Dickey EC, editor, Encyclopaedia of sensors. Intrinsically conducting polymers based electrochemical, vol. X. American Scientific Publishers, USA; 2006. p. 1-19
   Google Scholar
• Lavan A, McGuire T, Langer R. Small-scale systems for in vivo drug delivery. Nat Biotechnol 2003;10:1184-91
   Web of Science ®Google Scholar
• Esposito E, Fantin M, Marti M, Solid lipid nanoparticles as delivery systems for Bromocriptine. Pharm Res 2008;25:1521-30
   PubMed Web of Science ®Google Scholar
• Pillay S, Pillay V, Choonara Y, Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain. Pharm Nanotech 2009;382:277-90
   Google Scholar
• Linazasoro G. Neuroprotection and neurorescue in Parkinson's disease: love story or mission impossible? Exp Rev Neurother 2002;2:403-16
   PubMedGoogle Scholar
• Dugan L, Lovett G, Quick L, Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat Disord 2001;7:243-6
   PubMed Web of Science ®Google Scholar
• Bharali J, Klejbor I, Stachowiak K, Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. Proc Natl Acad Sci USA 2005;102:11539-44
   PubMed Web of Science ®Google Scholar
• Bai S, Thomas C, Rawat A, Ahsan F. Recent progress in dendrimer-based nanocarriers. Crit Rev Ther Drug Carrier Syst 2006;23:437-95
   PubMed Web of Science ®Google Scholar
• Luo D, Li Y. Dendrimer-like modular delivery vector. US20100136614; 2010
   Google Scholar
• Lee C, MacKay J, Frechet J, Szoka F. Designing dendrimers for biological applications. Nat Biotechnol 2005;23:1517-26
   PubMed Web of Science ®Google Scholar
• Gao Y, Gao G, He Y, Recent advances of dendrimers in delivery of genes and drugs. Mini Rev Med Chem 2008;8:889-900
   PubMed Web of Science ®Google Scholar
• Pereira AC, Green L, Nandi D, Aziz Z. Deep brain stimulation: indications and evidence. Expert Rev Med Device 2007;4(5):591-603
   PubMed Web of Science ®Google Scholar
• Toselli R, Thomas M, Fisher M. Endoscopic delivery of red/nir light to substantia nigra to treat Parkinson's disease. US0222067A1; 2009
   Google Scholar
• Xu J, Zhong N. Use of androgens for the treatment of parkinsons disease. US0325911; 2009
   Google Scholar
• Aderis Pharmaceuticals website. Available from: www.aderis.com/products/rotigotine.htm [Last accessed 12 January 2010]
   Google Scholar
• Vectura product pipeline and product profiles. Available from: www.vectura.com/vec/products/pipeline/profiles [Last accessed 14 January 2010]
   Google Scholar
• Apokyn website. Available from: www.apokyn.com/ [Last accessed 13 January 2010]
   Google Scholar
• Apo-go website. Available from: www.apo-go.co.uk/index.htm. [Last accessed 13 January 2010]
   Google Scholar